Clinical trials: Post-exposure Prophylaxis
Healthy Volunteers (Rabies Immunization)
Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year
The primary objective of the study is to demonstrate that a short intramuscular (IM) pre-exposure prophylaxis (PrEP) regimen is non-inferior to the reference IM PrEP regimen in terms of seroconversion rate.
- Trial name
- VAJ00001 (NCT03700242)
- Testing
- HDCV, PVRV
- Where
- 2 sites in Philippines
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, SARS-CoV-2 Infection
A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19
This study is to evaluate the efficacy of post-exposure prevention and safety of HH-120 nasal spray in participants who are caregivers of hospitalized patients infected with SARS-CoV-2.
- Trial name
- NCT05747677
- Testing
- HH-120 Nasal Spray
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Beijing Ditan Hospital
Respiratory Viral Infection, Respiratory Tract Diseases
PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
This is an open label controlled household-randomised trial designed to evaluate the efficacy of RESP301 alongside standard of care ("SOC") versus SOC alone.
- Conditions
- Respiratory Viral Infection, Respiratory Tract Diseases, COVID-19 Respiratory Infection
- Trial name
- PREVENT (NCT04842331)
- Testing
- RESP301 (a nitric oxide generating solution), Standard of Care (SOC)
- Where
- United Kingdom
- Sponsor
- Thirty Respiratory Limited
COVID-19
A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2
This study is open to adults living with a person who has tested positive for the coronavirus SARS-CoV-2. People who do not have symptoms of COVID-19 can take part in this study.
- Trial name
- NCT04894474
- Testing
- BI 767551 intravenous, BI 767551 inhalation
- Sponsor
- Boehringer Ingelheim
SARS-CoV Infection, COVID-19
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after…
- Trial name
- NCT05886816
- Testing
- Mitoquinone/mitoquinol mesylate
- Where
- United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Rabies
Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2.
- Trial name
- KAMRAB-003 (NCT02040090)
- Testing
- Active rabies vaccine (US-FDA approved)
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Kamada, Ltd.
Ebola Hemorrhagic Fever
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6002, a post-exposure prophylaxis candidate treatment for Ebolavirus.
- Trial name
- NCT01353027
- Testing
- AVI-6002
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Human Immunodeficiency Virus
Biomarkers for Event-driven PrEP Adherence
This study aims to recruit 40 participants who will take the combination anti-HIV drug tenofovir+emtricitabine (TDF/FTC) at specified times.
- Trial name
- NCT04298697
- Testing
- Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Emory University
Influenza, Human, Acute Respiratory Infection
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
The purpose of the study was to evaluate efficacy of prophylactic Ingavirin intake by people having contact with sick people infected with influenza and other acute respiratory viral infections
- Conditions
- Influenza, Human, Acute Respiratory Infection, Common Cold, Flu
- Trial name
- NCT03189537
- Testing
- Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)
- Where
- 2 sites in Russia
- Volunteers
- 400 people
- Sponsor
- Valenta Pharm JSC
HIV Seroconversion, Stimulant Abuse
Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men
This study seeks to evaluate the efficacy of a contingency management (CM) intervention compared to a yoked control condition for eliminating illicit stimulant use and for decreasing time to initiating post exposure prophylaxis…
- Trial name
- NCT01140880
- Testing
- Truvada
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Friends Research Institute, Inc.
COVID-19
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with…
- Trial name
- NCT04333225
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Influenza
Post-exposure Influenza Prophylaxis in a Hospital Setting
The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza in a hospital setting.
- Trial name
- NCT07496736
- Testing
- Oseltamivir
- Where
- Slovenia
- Volunteers
- 200 people
- Sponsor
- University Medical Centre Ljubljana
HIV Infections
Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission
The purpose of this study is to determine if extended antiretroviral regimens given to the infant during the first 14 weeks of age would decrease breast milk transmission of HIV.
- Trial name
- NCT00115648
- Testing
- Nevirapine, AZT, NVP and AZT
- Where
- Malawi
- Volunteers
- 3,300 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Prevention Program, Pre-Exposure Prophylaxis (PrEP)
Nurse-Led PrEP Initiation Among Incarcerated Individuals
PrEP is a medication that can help prevent the spread of HIV, but many who might benefit from PrEP do not take it. Individuals experiencing incarceration are interested in starting PrEP while incarcerated, but there are…
- Trial name
- SWIFT (NCT07781423)
- Testing
- Nurse-Led Intervention, Patient Navigation Intervention, Standard-of-care (SoC)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Rhode Island Hospital
Human Immunodeficiency Virus
Post-Exposure Prophylaxis in Health Care Workers
Objective: The objective of this study is to determine the safety and tolerability of Post-exposure Prophylaxis (PEP) with a regimen of Truvada + Kaletra among health care workers (HCWs) at Henry Ford Hospital.
- Trial name
- PEP (NCT01234116)
- Testing
- emtricitabine/tenofovir disoproxil fumarate
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
COVID-19, Viral Respiratory Illnesses
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2…
- Trial name
- NCT04359680
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 26 sites in United States
- Volunteers
- 1,407 people
- Sponsor
- Romark Laboratories L.C.
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077969
- Testing
- Famotidine, Celecoxib
- Where
- 15 sites in United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
Anthrax
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
The purpose of this Phase 3 clinical trial is to evaluate the immunogenicity and safety of BioThrax anthrax vaccine in healthy adults following 3 doses of BioThrax.
- Trial name
- NCT01491607
- Testing
- BioThrax
- Where
- 4 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Pertussis
Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure
The purpose of this study is to compare the effectiveness of two strategies of post-exposure prophylaxis (PEP) in healthcare workers (HCWs) who have been vaccinated with acellular pertussis vaccine and have been exposed to…
- Trial name
- VPES (NCT00469274)
- Testing
- Antibiotic PEP
- Where
- United States
- Volunteers
- 1,102 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Mother to Child HIV Transmission
Evaluation of Measurement of Maternal Viral Load at Delivery to Optimise Post-natal Prophylaxis of HIV-exposed Newborns
The main objective is to evaluate the operationality of introducing the measurement of viral load in HIV-1 infected mothers at delivery by POC to optimise post-natal prophylaxis and neonatal diagnosis of children according to the…
- Trial name
- IPOP (NCT05017558)
- Testing
- point of care
- Where
- Guinea
- Volunteers
- 70 people
- Sponsor
- ANRS, Emerging Infectious Diseases